Can We Discharge TAVR Patients the Same Day?

For over a decade, TAVR has been showing great benefits, but conduction abnormalities such as RBBB and prior A-V block, continue to be one of the biggest challenges, since in different series the need for definite pacemaker implantation (PPM) varies between 17 to 30% in the large, randomized studies of self-expanding valves.  

alta en el mismo día post TAVI

Even though we are well aware a higher implantation depth of the percutaneous valve (cusp overlapping) has been shown to significantly reduce the need for PPM, it has not yet been tested in large, randomized studies. 

68,482 patients receiving TAVR via femoral approach were looked at. 20,261 (29.6%) of these patients got early discharge (ED), between 0 and 1 day, and 48,221 late discharge (LD), ≥2 days.

Primary end point was rehospitalization for PPM. 

ED patients were younger (79 ± 8 years vs. 80 ± 7.6 years p < 0.01), there were more men, fewer were diabetic or presented kidney failure, COPD, peripheral vascular disease, or stroke, and had more programmed procedures. Besides, they presented fewer conduction abnormalities such as first and second-degree AV block, RBBB and fascicular blocks. 

Read also: Heparin Pretreatment in STEACS Treatment: A New Old Ally?

There were no differences in primary end point between ED and LD patients (2.0% vs. 1.8%; adjusted odds ratio: 1.15; 95% confidence interval: 0.95–1.39; p=0.15). Neither were there differences in readmissions for PPM at 30 and 60 days, or between elective and non-elective readmission. 

Mean time for readmission was 5 days, with no differences between ED and LD.

ED was associated to lower hospital expenses compared against LD.

Read also: RIPCORD 2 Study: Routine Assessment Using Pressure Wires in Acute Coronary Syndrome.

Predictors of PPM were 2-degree A-V block, fascicular blocks, RBBB and kidney failure. 

Conclusion

Early and late discharge TAVR patients who did not require permanent pacemaker implantation during hospitalization showed similar readmission rate for pacemaker implantation. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Early versus late discharge after transcatheter aortic valve replacement and readmissions for permanent pacemaker implantation. 

Reference: Ahmed M. Elzanaty, et al. Catheter Cardiovasc Interv. 2022;100:245–253.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...